Extrapleural Pneumonectomy (EPP)
Sarcomatoid Mesothelioma: A Clinicopathological and Immunohistochemical Study of 64 Cases
International Journal of Surgical Pathology 2021 May 3 [Link] Diana M Oramas, Michael Zaleski, Cesar A Moran Abstract Sixty-four cases of sarcomatoid pleural mesothelioma represent the basis of this study. The patients are 51 men and 13 women between the ages of 42 and 79 years, who presented with symptoms of chest pain, cough, and…
Read MoreThree Decades of Malignant Pleural Mesothelioma: An Academic Center Experience
Clinical Lung Cancer 2021 March 27 [Link] Abdullah Nasser, Andrew Baird, Mathieu D Saint-Pierre, Kayvan Amjadi, Scott Laurie, Paul Wheatley-Price Abstract Background: Malignant pleural mesothelioma (MPM) remains a challenging disease to manage. In the past few decades, extrapleural pneumonectomy (EPP), pemetrexed-based chemotherapy, and indwelling pleural catheters were introduced to MPM care with variable levels of…
Read MoreOutcomes of Conversion to Extrapleural Pneumonectomy from Pleurectomy/Decortication for Malignant Pleural Mesothelioma
Seminars in Thoracic and Cardiovascular Surgery 2021 February 17 [Link] Akifumi Nakamura, Masaki Hashimoto, Seiji Matsumoto, Nobuyuki Kondo, Takashi Kijima, Seiki Hasegawa Abstract In recent years, there has been a shift from extrapleural pneumonectomy (EPP) toward pleurectomy/decortication (P/D) as the preferred surgical technique. However, we occasionally encounter difficult cases wherein visceral pleurectomy requires conversion to…
Read MoreOutcomes of Conversion to Extrapleural Pneumonectomy from Pleurectomy/Decortication for Malignant Pleural Mesothelioma
Seminars in Thoracic and Cardiovascular Surgery 2021 February 17 [Link] Akifumi Nakamura, Masaki Hashimoto, Seiji Matsumoto, Nobuyuki Kondo, Takashi Kijima, Seiki Hasegawa Abstract In recent years, there has been a shift from extrapleural pneumonectomy (EPP) toward pleurectomy/decortication (P/D) as the preferred surgical technique. However, we occasionally encounter difficult cases wherein visceral pleurectomy requires conversion to…
Read MorePleurectomy Decortication in the Treatment of Malignant Pleural Mesothelioma: Encouraging Results and Novel Prognostic Implications Based on Experience in 355 Consecutive Patients
Annals of Surgery 2020 December 3 [Link] Moshe Lapidot, Ritu R Gill, Emanuele Mazzola, Samuel Freyaldenhoven, Scott J Swanson, Michael T Jaklitsch, David J Sugarbaker, Raphael Bueno Abstract Objective: We report a series of 355 consecutive patients treated over 9 years in a single institution with intended PDC. Background: Surgery for MPM has shifted from…
Read MoreDiagnostic Laparoscopy Improves Staging of Malignant Pleural Mesothelioma with Routine PET Imaging
Annals of Thoracic Surgery 2020 December 1 [Link] R Taylor Ripley, Nihanth Palivela, Shawn S Groth, Eugene A Choi, Lorraine D Cornwell, Phillip W Carrott, George Van Buren, Taylor G Splawn, David J Sugarbaker, Bryan M Burt Abstract Background: With a multimodal treatment strategy, cytoreductive surgery extends survival in malignant pleural mesothelioma. Improving the accuracy…
Read MoreDiagnostic Laparoscopy Improves Staging of Malignant Pleural Mesothelioma with Routine PET Imaging
Annals of Thoracic Surgery 2020 December 1 [Link] R Taylor Ripley, Nihanth Palivela, Shawn S Groth, Eugene A Choi, Lorraine D Cornwell, Phillip W Carrott, George Van Buren, Taylor G Splawn, David J Sugarbaker, Bryan M Burt Abstract Background: With a multimodal treatment strategy, cytoreductive surgery extends survival in malignant pleural mesothelioma. Improving the accuracy…
Read MoreProlonged survival after multimodal therapy for pleural mesothelioma: Don’t give up the follow-up. A case report
Annals of Medicine and Surgery 2020 November 11 [Link] Julien Guinde, Bertrand Chollet, Sophie Laroumagne, HervĂ© Dutau, Philippe Astoul Abstract Malignant Pleural mesothelioma (MPM) is a rare disease which is associated with a poor prognosis. Front line chemotherapy represents the cornerstone in the management of MPM, and the place of radical surgery is controversial and…
Read MoreProgress in the understanding of the immune microenvironment and immunotherapy in malignant pleural mesothelioma
Current Drug Targets 2020 July 18 [Link] Lei Cheng, Li Na, Xiao-Ling Xu, Wei-Min Mao Abstract Malignant pleural mesothelioma (MPM) is a remarkably aggressive thoracic malignancy with a limited survival of only 5-12 months. However, MPM still remains unresponsive to conventional standards of treatment, including pleurectomy and decortication, extrapleural pneumonectomy for resectable disease with or…
Read MoreSurgery for Mesothelioma After Radiation Therapy (SMART); A Single Institution Experience.
Frontiers in Oncology 2020 March 24 [Link] Breen WG, Garces YI, Olivier KR, Park SS, Merrell KW, Nichols FC, Peikert TD, Molina JR, Mansfield AS, Roden AC, Blackmon SH, Wigle DA Abstract Background: The optimal treatment sequence for localized malignant pleural mesothelioma (MPM) is controversial. We aimed to assess outcomes and toxicities of treating localized…
Read More